Clinical Trial

The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2025 (before its estimated June 13, 2025 completion). Its status may not reflect the trial's current state.
Summary
Research Background: According to the Myasthenia Gravis Foundation of America (MGFA, 2015), the estimated prevalence of myasthenia gravis is 14-20 per 100,000 people, with a higher prevalence in young female individuals compared to males. However, as individuals age, especially after the age of 50, the prevalence in males becomes higher than in females. myasthenia gravis patients often experience varying degrees of disability, leading to the need for long-term medical care, medication, and lifestyle adjustments. This also gives rise to subsequent challenges in caregiving, affecting both the patients' families and society.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-11.
Trial Details
NCT Number NCT06881173
Lead Sponsor Cheng, yu-ting
Conditions Myasthenia Gravis
Enrollment 112 participants
Start Date 2022-06-14
Primary Completion 2025-06-13 (estimated)
Study Completion 2025-06-13 (estimated)
Updated on ClinicalTrials.gov 2025-03-20